A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumours
A Phase 1, first-in-human, SRF617 monotherapy and combination therapy, dose escalation, safety, and tumour biopsy expansion study of SRF617, an antibody that inhibits CD39 activity, in patients with advanced solid tumours. Inhibition of CD39 activity may improve the ability to mount an immune response against tumour cells.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society